Development and Validation of Small‐diameter Vascular Tissue From a Decellularized Scaffold Coated With Heparin and Vascular Endothelial Growth Factor
- 23 February 2009
- journal article
- research article
- Published by Wiley in Artificial Organs
- Vol. 33 (3) , 230-239
Abstract
To overcome shortcomings of current small‐diameter vascular prostheses, we developed a novel allogenic vascular graft from a decellularized scaffold modified through heparin immobilization and vascular endothelial growth factor (VEGF) coating. The VEGF coating and release profiles were assayed by enzyme‐linked immunosorbent assay, the biological activity of modified surface was validated by human umbilical vein endothelial cells seeding and proliferation for 10 days in vitro. In vivo, we implanted either a modified or a nonmodified scaffold as bilateral carotid allogenic graft in canines (n = 15). The morphological examination of decellularized scaffolds showed complete removal of cellular components while the extracellular matrix structure remained intact. After modification, the scaffolds possessed local sustained release of VEGF up to 20 days, on which the cells cultured showed significantly higher proliferation rate throughout the time after incubation compared with the cells cultured on nonmodified scaffolds (P < 0.0001). After 6 months of implantation, the luminal surfaces of modified scaffolds exhibited complete endothelium regeneration, however, only a few disorderly cells and thrombosis overlay the luminal surfaces of nonmodified scaffolds. Specifically, the modified scaffolds exhibited significantly smaller hyperplastic neointima area compared with the nonmodified, not only at midportion (0.56 ± 0.07 vs. 2.04 ± 0.12 mm2, P < 0.0001), but also at anastomotic sites (1.76 ± 0.12 vs. 3.67 ± 0.20 mm2, P < 0.0001). Moreover, modified scaffolds had a significantly higher patency rate than the nonmodified after 6 months of implantation (14/15 vs. 7/15, P = 0.005). Overall, this modified decellularized scaffold provides a promising direction for fabrication of small‐diameter vascular grafts.Keywords
This publication has 28 references indexed in Scilit:
- Implantation of Decellularized Small‐caliber Vascular Xenografts With and Without Surface Heparin TreatmentArtificial Organs, 2007
- Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGFBiomaterials, 2006
- In Vivo Recellularization of Plain Decellularized Xenografts With Specific Cell Characterization in the Systemic Circulation: Histological and Immunohistochemical StudyArtificial Organs, 2006
- The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matricesBiomaterials, 2006
- Vascular Endothelial Growth Factor Regulates Reendothelialization and Neointima Formation in a Mouse Model of Arterial InjuryCirculation, 2004
- Basic Fibroblast Growth Factor Coating and Endothelial Cell Seeding of a Decellularized Heparin‐coated Vascular GraftArtificial Organs, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Tissue Engineering of Vascular Grafts: Human Cell Seeding of Decellularised Porcine MatrixEuropean Journal of Vascular and Endovascular Surgery, 2000
- What is the proper role of polytetrafluoroethylene grafts in infrainguinal reconstruction?Journal of Vascular Surgery, 1989
- Suppression by heparin of smooth muscle cell proliferation in injured arteriesNature, 1977